Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

Industry Overview - The Medical-Biomedical and Genetics industry is currently ranked 73 out of more than 250 industries according to Zacks Industry Rank, indicating a strong position relative to other segments [1][2] Company Performance - AnaptysBio has experienced positive earnings estimate revisions, with current quarter estimates improving from a loss of $1.57 per share to a loss of $1.56 per share, and current year estimates narrowing from a loss of $6.46 per share to a loss of $6.25 per share [2] - The company holds a Zacks Rank of 3 (Hold), which is considered a favorable signal for investors [2]